RxDoctor Payments Data

Kassie Simmons

Family · Chadbourn, NCNPI 1013542315

Payments from drug & device makers

$912in general payments, 2019–2025

Across 50 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$184
  • Novo Nordisk$152
  • Otsuka America Pharmaceutical, Inc.$152
  • Amgen$116
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • Ardelyx, Inc.$66
  • plus $175 from 6 others

What the payments were for

  • Food & beverage$912100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$912 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,839
Medicare patients
35
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$207,555
MounjaroTirzepatide130$141,543
FarxigaDapagliflozin Propanediol113$80,798
Breztri AerosphereBudesonide/Glycopyr/Formoterol90$66,134
LinzessLinaclotide84$56,535
RexultiBrexpiprazole27$37,218
EliquisApixaban47$25,424
JardianceEmpagliflozin39$22,568
TrulicityDulaglutide22$21,920
XareltoRivaroxaban29$17,397
VraylarCariprazine Hcl11$15,486
JanuviaSitagliptin Phosphate18$14,259
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate13$13,685
Repatha SureclickEvolocumab21$12,259
MyrbetriqMirabegron25$11,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$152$207,555192 claims
Lilly USA, LLCMounjaro, Trulicity$15$163,463152 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$184$154,513233 claims
AbbVieLinzess, Vraylar$50$72,02195 claims
Otsuka America Pharmaceutical, Inc.Rexulti$152$37,21827 claims
Astellas Pharma US IncMyrbetriq$21$11,13425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Chadbourn

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →